2. Academic Validation
  3. BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma

BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma

  • Blood Adv. 2025 Jul 2:bloodadvances.2024015322. doi: 10.1182/bloodadvances.2024015322.
Claudia Pignataro 1,  Pietro Zoppoli 1,  Luca Vincenzo Cappelli 2,  Liron Yoffe 3,  Marta Moretti 4,  Mariapaola Izzo 4,  Selene Mallia 5,  Clarisse Kayembe 3,  Abigail Taylor 3,  Gianluca Petrillo 1,  Alessandra Affinito 1,  Cristina Quintavalle 6,  Giada De Luca 6,  Martina Mascolo 1,  Sara Verde 7,  Aurelia Fraticelli 7,  Alessia Ciarrocchi 8,  Paolo Salerno 1,  Enrico De Smaele 9,  Antonio Francesco Campese 10,  Valentina Fragliasso 11,  Robin Foà 12,  Giuseppe Merla 1,  Giorgio Ga Inghirami 3,  Gerolama Condorelli 13,  Danilo Fiore 1
Affiliations

Affiliations

  • 1 University of Naples Federico II, Napoli, Italy.
  • 2 Sapienza University, Rome, Rome, Italy.
  • 3 Weill Cornell Medicine, New York, New York, United States.
  • 4 Sapienza University of Rome, Rome, Italy.
  • 5 Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • 6 Consiglio Nazionale delle Ricerche (CNR), Napoli, Italy.
  • 7 University of Rome "Tor Vergata", Rome, Italy.
  • 8 Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • 9 La Sapienza University of Rome, Rome, Italy.
  • 10 Sapienza, University of Rome, Roma, Italy.
  • 11 Azienda USL-IRCCS, Reggio Emilia, Italy.
  • 12 Hematology, Sapienza University of Rome, Rome, Italy.
  • 13 University of Naples federico II, Naples, Italy.
PMID: 40601898 DOI: 10.1182/bloodadvances.2024015322
Abstract

Resistance to first-line chemotherapies and crizotinib in anaplastic large cell lymphoma (ALCL) represents a significant challenge, often leading to a dismal outcome. Despite recent advancements, the dissection of the intrinsic and extrinsic molecular alterations underlying crizotinib resistance in ALCL is still poorly understood. Here, we transcriptionally unraveled the bidirectional interplay between anaplastic lymphoma kinase (ALK)-driven ALCL (ALK+ ALCL) and stromal cells in the presence of crizotinib at bulk and single-cell levels, and identified that the microenvironment provides pro-survival signals leading to crizotinib persistence in ALK+ ALCL. We detected increased BCL2 expression, and downregulation of pathways related to Apoptosis in crizotinib-persister ALK+ ALCL cells. Further, we predicted in silico the ligand-receptor interactions between tumoral and stromal cells, supporting their contribution to ALCL pathogenesis mainly participating in the adhesion/membrane transport, triggering receptors, and promoting activation and microenvironment stimulation in lymphoma cells. Finally, we explored the effect of crizotinib in combination with BH3 mimetics. Pharmacologic and genetic ablation of anti-apoptotic targets displayed a significant synergistic effect with crizotinib, overcoming the stroma-mediated protection of lymphoma cells upon drug treatment. Thus, BCL2/Bcl-xL targeting is synthetic lethal with crizotinib exposure in ALK+ ALCL and represents an intrinsic and extrinsic-mediated targetable vulnerability in lymphoma cells challenged with crizotinib. Our data supports the evaluation of BCL2 targeting in crizotinib-based regimens in the management of ALK+ ALCL patients.

Figures
Products